Skip to main content

Vonvendi FDA Approval History

FDA Approved: Yes (First approved December 8, 2015)
Brand name: Vonvendi
Generic name: von willebrand factor (recombinant)
Dosage form: for Injection
Company: Takeda Pharmaceutical Company Limited
Treatment for: von Willebrand Disease

Last updated by Judith Stewart, BPharm on Sep 9, 2025.

Vonvendi (von Willebrand factor (recombinant)) is a recombinant von Willebrand factor for the treatment of von Willebrand disease (VWD).

Add as a preferred source on Google Google preffered source badge

Development timeline for Vonvendi

DateArticle
Sep  5, 2025Approval U.S. FDA Approves Expanded Indication for Vonvendi [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
Jan 31, 2022Approval FDA Approves Prophylactic Treatment with Vonvendi [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
Apr 17, 2018Approval FDA Approves Vonvendi [von Willebrand factor (recombinant)] for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease
Dec  8, 2015Approval FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

See also

Vonvendi (von willebrand factor (recombinant)) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer